The NAPOLI-1 Phase III study was conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. The primary log-rank analysis of overall survival was statistically significant
Preclinical data that supported this approval will be presented in a poster session at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) on 6 May
The option grants the potential commercial partner an exclusive, time-limited right to negotiate, in good faith, the terms of a definitive license agreement with respect to development, distribution
The award supports preclinical studies to confirm that Oricula’s new chemical entities are both safe and effective for hearing protection. When complete, the results will form the basis
Medpace Laboratories, Singapore will serve and support new and existing Medpace pharmaceutical clients conducting clinical research in the rapidly expanding Asia Pacific region. With dedicated project management and
The total transaction value is approximately $100m. At closing, ACETO paid $80m in cash, adjusted for working capital, and $5m in ACETO stock. The definitive purchase agreement also
SAA is a rare disorder in which the bone marrow fails to make enough new blood cells. There are no approved therapies available for SAA patients who are
The patent application governs composition of matter for KP511, KemPharm’s prodrug of hydromorphone. KP511 is the second most advanced product candidate in KemPharm’s pain therapy portfolio, which includes
Nanobind is an inexpensive thermoplastic nanomaterial developed for high integrity DNA and RNA extraction. Its hierarchical structure of microscale folds topped by nanoscale wrinkles creates a high binding
The 2014 SWF Research Grants will support research conducted by two prominent investigators over two years. The grants are the largest awarded by the Sturge-Weber Foundation to date.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.